Every Form 4 that Fennec Pharmaceuticals Inc. (FENC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.
Fennec Pharmaceuticals Inc. Chief Medical Officer Pierre Sargis Sayad had 168 Common Shares released from restriction on September 30, 2026, from shares awarded March 28, 2025. His direct holdings after the transaction were 9,687 shares. The transaction is reported as an award-related acquisition, rather than a market purchase; no Rule 10b5-1 plan is reported.
Fennec Pharmaceuticals Inc. Chief Commercial Officer Terry L. Evans reported an acquisition of 168 common shares on September 30, 2026. The shares were released from restriction from shares awarded March 28, 2025. Evans held 21,687 common shares directly after the transaction.
Fennec Pharmaceuticals Inc. (FENC) Chief Executive Officer Jeffrey S. Hackman had 1,159 Common Shares released from restriction on September 30, 2026. The shares came from an award dated March 28, 2025. After the transaction, he directly held 67,461 Common Shares. The reported action was an award-related acquisition.
Fennec Pharmaceuticals Inc. Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on September 30, 2026, as shares released from restriction from shares awarded March 28, 2025. She directly held 24,800 shares following the transaction. The reported per-share price was $0.0000; this was an award-related restriction release, not a market purchase.
Fennec Pharmaceuticals Inc. Chief Financial Officer Robert Andrade reported acquiring 1,703 common shares on September 30, 2026. The shares were released from restriction from awards dated May 16, 2024, and March 28, 2025. His reported direct holdings after the transaction were 243,009 common shares; the reported per-share price was $0.0000.
FENNEC PHARMACEUTICALS INC. (FENC) director Marco Maria Brughera exercised stock options for 15,545 common shares on September 15, 2026 at an exercise price of $2.11 per share and sold 15,545 common shares at $10.29 per share, all pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2026. Following the option exercise, he held 220,000 stock options directly.
FENNEC PHARMACEUTICALS INC. (FENC) reported that former director Rosty Raykov had two non-derivative transactions in common shares. On 2026-08-31, he acquired 2,778 common shares at $0.00 per share, representing shares released from restriction from an award granted on May 16, 2024. On 2026-09-01, he sold 10,000 common shares at $12.11 per share in a transaction described as a sale in the open market or a private transaction, executed pursuant to a Rule 10b5-1 trading plan dated September 19, 2025.
FENNEC PHARMACEUTICALS INC. (FENC) reported insider activity by Chief Medical Officer Pierre Sargis Sayad on 2026-08-31. He acquired 168 common shares at $0.00 per share upon release of restrictions from a prior award, and sold 12,000 previously vested restricted and performance shares at $12.18 per share. Net activity reflects a larger sale than acquisition, and resulting share holdings were not stated.
FENNEC PHARMACEUTICALS INC. (FENC) reported an insider equity change by Chief Commercial Officer Terry L. Evans. On 2026-08-31, Evans acquired 168 Common Shares at a reported price of $0.00 per share, reflecting shares released from restriction related to an award originally granted on 2025-03-28. Following this release, Evans directly holds 21,519 Common Shares of Fennec Pharmaceuticals Inc.
FENNEC PHARMACEUTICALS INC. (FENC) reported that Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on 2026-08-31 through a grant, award, or other acquisition transaction at a stated price of $0.00 per share. A footnote explains these are shares released from restriction from shares awarded on 2025-03-28, bringing her direct holdings to 24,644 common shares.
FENNEC PHARMACEUTICALS INC. (FENC) reported that Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares on August 31, 2026 in a transaction classified as a grant, award, or other acquisition. The shares were released from restriction relating to shares originally awarded on March 28, 2025.
Following this release, Hackman directly holds 66,302 Common Shares of FENNEC PHARMACEUTICALS INC. The transaction carried a reported per-share price of $0.00, consistent with a compensatory share award rather than an open-market purchase, and was not reported under a Rule 10b5-1 trading plan.
FENNEC PHARMACEUTICALS INC. (FENC) reported an insider equity transaction by Chief Financial Officer Robert Andrade. On 2026-08-31, Andrade acquired 1,703 common shares at a reported price of $0.00 per share, characterized as a grant or award. A footnote states these shares represent releases from restrictions on shares originally awarded on 2024-05-16 and 2025-03-28. Following this release, Andrade directly holds 241,306 common shares.
FENNEC PHARMACEUTICALS INC. (FENC) reported insider activity by Chief Financial Officer Robert Andrade. On August 28, 2026, he exercised 21,928 stock options at an exercise price of $5.10 per share, acquiring the same number of common shares, and held 779,330 stock options directly after this exercise. On August 27, 2026, he sold 75,000 common shares at $11.78 per share pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026, with a portion of the proceeds used to pay his tax obligations.
FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov sold 10,000 common shares on 2026-08-03 at $9.5800 per share in a sale classified as an open-market or private transaction. The sale was executed under a Rule 10b5-1 plan dated September 19, 2025, and left him holding 131,633 common shares directly.
Fennec Pharmaceuticals Inc. reported that Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on July 31, 2026 through a release of restrictions on shares originally awarded on March 28, 2025. The award had a stated per-share price of $0.00, increasing his direct ownership to 21,351 Common Shares.
Fennec Pharmaceuticals reported that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded 3/28/2025. After this vesting event, Evans directly holds 21,351 Common Shares, with no Rule 10b5-1 trading plan indicated.
Fennec Pharmaceuticals Inc. reported that Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares on July 31, 2026 through the release of restrictions on shares awarded March 28, 2025 at a stated price of $0.0000 per share. After this compensation-related release, she directly holds 24,488 common shares.
Fennec Pharmaceuticals Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded on March 28, 2025. Following this equity compensation event, his direct holdings total 65,143 Common Shares at a reported transaction price of $0.0000 per share.
FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov acquired 2,778 common shares on 2026-07-31 in a transaction coded as a grant or award. The shares represent stock released from restriction from an award granted on 5/16/2024, bringing his direct holdings to 141,633 common shares.
FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares on July 31, 2026 via a grant/award at a stated price of $0.0000 per share. A footnote explains these shares were released from restrictions on awards granted May 16, 2024 and March 28, 2025. After this release, Andrade directly holds 292,675 common shares.
FENNEC PHARMACEUTICALS INC. former director Rosty Raykov reported several equity transactions in common shares. He exercised stock options to acquire 15,597 shares at $2.45 per share and received 2,778 additional shares released from prior restricted awards. On the same date, he sold 9,599 shares at $10.41 per share to satisfy tax obligations, with these actions carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After these transactions, he directly holds 138,855 common shares.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported an equity compensation transaction involving the company’s common shares. On the reported date, Evans acquired 168 common shares through a grant, award, or other acquisition, with no cash price shown for the shares.
Following this award, Evans directly holds 21,183 common shares. A footnote explains that the 168 shares represent shares released from restriction from an award originally granted on March 28, 2025, indicating this is part of a previously approved compensation arrangement rather than an open‑market trade.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported a compensation-related stock transaction. He acquired 168 Common Shares at $0.00 per share as a grant or award, representing shares released from restriction on an award originally granted on March 28, 2025. Following this vesting event, he directly holds 21,183 Common Shares. This is a routine equity compensation release rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported a compensation-related share acquisition. On June 30, 2026, he received 1,159 Common Shares at no purchase price, reflecting shares released from restriction from an award granted on March 28, 2025. Following this release, he directly owns 63,984 Common Shares. This filing records a routine equity award release rather than an open-market trade.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade reported a compensation-related share event. He acquired 1,703 common shares at a price of $0.00 per share through a grant/award acquisition, representing shares released from restrictions on prior awards. Following this release, he directly holds 290,972 common shares.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a routine equity compensation event. She acquired 156 common shares at no cost in a grant or award transaction, bringing her direct holdings to 24,332 common shares. The shares represent a release from restrictions on stock previously awarded on March 28, 2025.
FENNEC PHARMACEUTICALS INC. director Marco Maria Brughera received a grant of stock options as part of his compensation. On June 10, 2026, he was awarded a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share, fully vested on the grant date. Following this grant, his reported option holdings increased to 235,545 derivative securities, indicating this is a routine equity incentive award rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. director Jodi A. Cook received a compensation-related grant of stock options. On June 10, 2026, Cook was granted a non-qualified stock option to purchase 20,000 common shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan. The option is 100% vested on the grant date and expires on June 10, 2036. Following this award, Cook holds stock options covering a total of 160,000 shares.
FENNEC PHARMACEUTICALS INC. director Khalid Islam received a grant of stock options as part of his equity compensation. On June 10, 2026, he was awarded a non-qualified stock option to purchase 25,000 Common Shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan. The option is fully vested on the grant date and expires on June 10, 2036. Following this award, Islam holds stock options covering a total of 250,000 shares.
FENNEC PHARMACEUTICALS INC. director Chris A. Rallis received a compensation-related stock option grant. On June 10, 2026, he was granted a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan.
The option is 100% vested on the grant date and expires on June 10, 2036. Following this award, Rallis holds stock options for a total of 200,000 shares, according to the filing. This is an equity grant, not an open-market share purchase.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported a series of routine equity compensation transactions. He received 2,778 common shares at no cost from the release of previously awarded restricted shares, then exercised 15,597 stock options at $2.45 per share.
To cover tax obligations tied to the option exercise, 9,747 common shares were sold at $9.62 per share pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2025. Following these transactions, Raykov directly holds 130,079 common shares and 1,556,195 stock options.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a small share award under the company’s equity compensation. On May 31, 2026, she acquired 156 common shares at $0.00 per share, representing shares released from restriction from an award granted on March 28, 2025. Following this vesting-related acquisition, she directly holds 24,176 common shares, indicating a routine, compensation-driven increase in her ownership rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported a compensation-related stock event. On May 31, 2026, Evans acquired 168 Common Shares at a stated price of $0.00 per share, characterized as a grant, award, or similar acquisition.
According to the filing, these shares represent a release from restriction on shares originally awarded on March 28, 2025. Following this transaction, Evans directly holds a total of 21,015 Common Shares of Fennec Pharmaceuticals, reflecting a routine increase in his equity-based compensation holdings rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Sayad Pierre Sargis acquired 168 Common Shares through a grant classified as a “grant, award, or other acquisition.” The shares were released from restriction on equity originally awarded on 3/28/2025 and carried no purchase price.
Following this compensation-related acquisition, Sargis directly holds 21,015 Common Shares. The event reflects routine equity compensation rather than an open‑market share purchase or sale.
Fennec Pharmaceuticals Inc. reported that Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares as a grant or award. The shares were released from restriction from an award originally granted on 3/28/2025 and carried a transaction price of $0.00 per share.
Following this compensation-related acquisition, Hackman directly owns 62,825 Common Shares. The filing reflects routine equity compensation rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares as a grant or award on May 31, 2026. The shares were released from restrictions tied to prior awards dated May 16, 2024 and March 28, 2025, and carried no purchase price. After this vesting event, Andrade directly holds 289,269 common shares.
FENNEC PHARMACEUTICALS INC. director Chris A. Rallis reported an option exercise combined with a related share sale. He exercised stock options covering 14,344 Common Shares at $2.44 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025. To cover tax obligations from this exercise, 8,346 Common Shares were sold at an average price of $7.04 per share. After these transactions, Rallis directly holds 63,077 Common Shares, reflecting a net increase in his equity position from the option exercise.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported an options-related share transaction in FENC. He exercised stock options to acquire 15,598 common shares at $2.45 per share and also received 2,778 previously restricted shares. On the same day, he sold 10,781 common shares in an open-market sale at $6.47 per share to satisfy tax obligations related to the option exercise, all under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. Following these transactions, Raykov directly holds 121,451 common shares.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans acquired 168 Common Shares through an exercise or conversion of a derivative security at a stated price of $0.00 per share. A footnote explains these represent shares released from restriction from shares awarded on 3/28/2025. Following this transaction, Evans directly holds 20,847 Common Shares.
Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion. On April 30, 2026, 155 common shares were released from restriction from shares awarded on March 28, 2025, increasing her directly held stake.
Following this release, Cioffi directly owns 24,020 common shares. The transaction reflects routine equity-based compensation vesting rather than an open-market purchase, as the reported price per share was $0.0000.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.
After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade acquired 1,703 common shares on April 30, 2026 through an exercise or conversion of a derivative security reported at $0.00 per share.
After this transaction, Andrade directly owns 287,566 common shares. A footnote explains these shares were released from restriction from awards originally granted on May 16, 2024 and March 28, 2025.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on April 30, 2026 through the release of restricted shares that were originally awarded on March 28, 2025. After this compensation-related share release, he directly owns a total of 20,847 Common Shares.
Cioffi Christiana Marie reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported compensation-related equity awards. She received incentive stock options for 120,000 common shares at $5.77 per share, expiring on March 31, 2036, under the 2020 Equity Incentive Plan. Performance share units and previously awarded restricted shares also vested, increasing her directly held common shares to 23,865 as of March 28, 2026.
FENNEC PHARMACEUTICALS INC. reported that Chief Executive Officer Jeffrey S. Hackman received an incentive stock option grant to purchase 200,000 common shares at $5.77 per share, expiring on March 31, 2036, under the company’s 2020 Equity Incentive Plan.
On March 31, 2026, one-third of these options become exercisable, with additional portions vesting monthly so that all 200,000 options are vested by March 31, 2029. Hackman also acquired additional common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025.
FENNEC PHARMACEUTICALS director Rosty Raykov exercised stock options and sold shares in a largely pre-planned, tax-related transaction. On April 1, 2026, he exercised 15,598 stock options at $2.45 per share, acquiring the same number of common shares under a Rule 10b5-1 trading plan adopted on September 19, 2025. On the same date, he sold 10,946 common shares at $6.31 per share to satisfy tax obligations related to the option exercise, also under that plan. A day earlier, on March 31, 2026, he received 5,208 common shares as a grant released from prior restricted awards. After these trades, he directly owned 113,856 common shares, indicating he retained most of the exercised shares.
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L Evans received an incentive stock option grant covering 120,000 common shares at an exercise price of $5.77 per share. The options were granted under the 2020 Equity Incentive Plan and vest over time, with one-third exercisable as of March 31, 2027 and the remainder vesting monthly so that all are vested by March 31, 2029.
On the same date, Evans also acquired common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025. Following these equity awards and releases, Evans directly holds 20,679 common shares and 270,000 stock options, reflecting routine compensation-related transactions rather than open-market buying or selling.
Andrade Robert reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. reported insider equity awards for Chief Financial Officer Robert Andrade. On March 31, 2026, he received incentive stock options to purchase 120,000 common shares at $5.77 per share under the 2020 Equity Incentive Plan, vesting monthly from March 31, 2027 until March 31, 2029.
On the same date, 14,724 common shares were issued from settlement of PSUs that vested, and 2,213 common shares were released from restriction from prior awards. On March 28, 2026, 12,270 additional common shares were released from restriction from a 2025 award. Following these transactions, he directly holds 273,593 common shares and 921,045 stock options.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.